文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-LNC1003用于中等水平PSMA表达前列腺癌的放射性配体治疗开发

Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-04-25

本研究基于PSMA靶向剂和伊文思蓝合成[177Lu]Lu-LNC1003,在22Rv1中等PSMA表达肿瘤模型中验证其结合亲和力与靶向特异性。SPECT/CT显像和生物分布显示[177Lu]Lu-LNC1003肿瘤摄取显著高于[177Lu]Lu-EB-PSMA-617和[177Lu]Lu-PSMA-617;单次18.5 MBq给药可显著抑制22Rv1肿瘤生长,而同等条件[177Lu]Lu-PSMA-617无明显抗肿瘤效果。

要点

  • LNC1003对PSMA的IC50为10.77 nM,与PSMA-617(27.49 nM)和EB-PSMA-617(7.91 nM)相当。
  • 注射后24小时[177Lu]Lu-LNC1003肿瘤摄取为138.87 ± 26.53%ID/g,高于[177Lu]Lu-EB-PSMA-617(29.89 ± 8.86%ID/g)和[177Lu]Lu-PSMA-617(4.28 ± 0.25%ID/g)。
  • 单次18.5 MBq [177Lu]Lu-LNC1003显著抑制22Rv1肿瘤生长,同等条件[177Lu]Lu-PSMA-617无明显抗肿瘤效果。

核心结论

  • [177Lu]Lu-LNC1003成功合成且放射化学纯度高、稳定性好,体外和体内均显示高结合亲和力和PSMA靶向特异性。
  • 凭借大幅增强的肿瘤摄取和滞留,[177Lu]Lu-LNC1003有潜力以显著更低剂量和更少周期的177Lu提高疗效,有望临床转化用于治疗不同PSMA表达水平的前列腺癌。

研究设计与样本

  • 临床前研究:基于PSMA靶向剂和伊文思蓝合成[177Lu]Lu-LNC1003。
  • 在22Rv1中等PSMA表达肿瘤模型中通过细胞摄取和竞争结合实验验证结合亲和力与PSMA靶向特异性。
  • 在22Rv1荷瘤小鼠中进行SPECT/CT显像和生物分布研究评估临床前药代动力学,并进行放射性配体治疗研究评估疗效。

主要发现

  • LNC1003体外对PSMA的IC50为10.77 nM,与PSMA-617(IC50=27.49 nM)和EB-PSMA-617(IC50=7.91 nM)相当。
  • [177Lu]Lu-LNC1003的SPECT显像显示肿瘤摄取和滞留较[177Lu]Lu-EB-PSMA和[177Lu]Lu-PSMA-617显著改善。
  • 生物分布研究显示注射后24小时[177Lu]Lu-LNC1003肿瘤摄取为138.87 ± 26.53%ID/g,高于[177Lu]Lu-EB-PSMA-617(29.89 ± 8.86%ID/g)和[177Lu]Lu-PSMA-617(4.28 ± 0.25%ID/g)。
  • 靶向放射性配体治疗结果显示单次给予18.5 MBq [177Lu]Lu-LNC1003后22Rv1肿瘤生长显著抑制。
  • 同等条件下[177Lu]Lu-PSMA-617治疗后无明显抗肿瘤效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evans blue as an albumin binder has been widely used to improve pharmacokinetics and enhance tumor uptake of radioligands, including prostate-specific membrane antigen (PSMA) targeting agents. The goal of this study is to develop an optimal Evans blue-modified radiotherapeutic agent that could maximize the absolute tumor uptake and tumor absorbed dose thus the therapeutic efficacy to allow treatment of tumors even with moderate level of PSMA expression. METHODS: [177Lu]Lu-LNC1003 was synthesized based on PSMA-targeting agent and Evans blue. Binding affinity and PSMA targeting specificity were verified through cell uptake and competition binding assay in 22Rv1 tumor model that has moderate level of PSMA expression. SPECT/CT imaging and biodistribution studies in 22Rv1 tumor-bearing mice were performed to evaluate the preclinical pharmacokinetics. Radioligand therapy studies were conducted to systematically assess the therapeutic effect of [177Lu]Lu-LNC1003. RESULTS: LNC1003 showed high binding affinity (IC50 = 10.77 nM) to PSMA in vitro, which was comparable with that of PSMA-617 (IC50 = 27.49 nM) and EB-PSMA-617 (IC50 = 7.91 nM). SPECT imaging of [177Lu]Lu-LNC1003 demonstrated significantly improved tumor uptake and retention as compared with [177Lu]Lu-EB-PSMA and [177Lu]Lu-PSMA-617, making it suitable for prostate cancer therapy. Biodistribution studies further confirmed the remarkably higher tumor uptake of [177Lu]Lu-LNC1003 (138.87 ± 26.53%ID/g) over [177Lu]Lu-EB-PSMA-617 (29.89 ± 8.86%ID/g) and [177Lu]Lu-PSMA-617 (4.28 ± 0.25%ID/g) at 24 h post-injection. Targeted radioligand therapy results showed noteworthy inhibition of 22Rv1 tumor growth after administration of a single dose of 18.5 MBq [177Lu]Lu-LNC1003. There was no obvious antitumor effect after [177Lu]Lu-PSMA-617 treatment under the same condition. CONCLUSION: In this study, [177Lu]Lu-LNC1003 was successfully synthesized with high radiochemical purity and stability. High binding affinity and PSMA targeting specificity were identified in vitro and in vivo. With greatly enhanced tumor uptake and retention, [177Lu]Lu-LNC1003 has the potential to improve therapeutic efficacy using significantly lower dosages and less cycles of 177Lu that promises clinical translation to treat prostate cancer with various levels of PSMA expression.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wen X, Xu P, Zeng X, et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023. PMID: 37097443. doi:10.1007/s00259-023-06229-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。